GleamWall
中文EN

TELO Telomir Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1971532 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY51.3%
TTM EPS YoY-159.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-96.3%
ROA-91.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets5.1%
Debt / equity0.00x
Current ratio19.60x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-15.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$2.44M$2.24M
SG&A expense$8.10M$9.64M
Interest expense—$4.34M
Net income-$10.41M-$16.53M
EPS (basic)-0.33-0.56
EPS (diluted)-0.33-0.56
Weighted avg. shares (diluted)31.65M29.54M
Balance sheet
Cash & equivalents$7.29M$1.27M
Current assets$7.34M$1.32M
Total assets$7.34M$1.32M
Current liabilities$1.43M$680,968
Total liabilities$1.43M$680,968
Shareholders' equity$5.91M$643,037
Shares outstanding34.38M29.76M
Cash flow statement
Operating cash flow-$3.69M-$5.07M
Financing cash flow$9.71M$6.34M
Stock-based compensation$5.29M$6.87M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.